权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac Sarcoidosis

心脏磁共振成像引导心脏结节病的风险分层

基本信息

批准号：
10472465
负责人：
Chetan N Shenoy
金额：
$ 7.75万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-20 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10472465
关键词：
Accounting Adverse event Affect American Arrhythmia Biological Markers Biopsy Cardiac Cardiac Death Cardiac Sarcoidosis Cardiovascular system Cessation of life Characteristics Clinical Clinical Management Cluster Analysis Data Devices Diagnosis Disease Etiology Evaluation Finland Funding Gadolinium Goals Granulomatous disease Heart Transplantation Heart failure Histologic Hospitalization Hospitals Immunosuppression Implantable Defibrillators Infection Inflammatory Literature Magnetic Resonance Imaging Methods Minnesota Minority Myocardial Observational Study Outcome Pathology Patient-Focused Outcomes Patients Pharmaceutical Preparations Phenotype Predisposition Prospective Studies Quality of life Registries Research Risk Sarcoidosis Shock Testing Toxic effect Universities Ventricular Arrhythmia Work adverse outcome base cardiac magnetic resonance imaging cardiology service clinical diagnosis cohort demographics heart damage high risk image guided implantation improved left ventricular assist device magnetic resonance imaging biomarker mortality patient stratification prevent prognostic tool prognostic value prospective racial diversity randomized trial risk stratification side effect sudden cardiac death

项目摘要

PROJECT SUMMARY/ABSTRACT An estimated 200,000 Americans live with sarcoidosis. Sarcoidosis is a multisystem granulomatous disease of unknown etiology. Up to a quarter of patients with sarcoidosis may have cardiac involvement. Cardiac sarcoidosis is the second leading cause of sarcoidosis-related mortality, accounting for up to a quarter of deaths from sarcoidosis. Most deaths from cardiac sarcoidosis are due to ventricular arrhythmias. Cardiovascular magnetic resonance imaging is frequently used in the evaluation of patients with suspected or known cardiac sarcoidosis. In this proposal, we aim to investigate cardiovascular magnetic resonance imaging biomarkers that may be associated with adverse outcomes in patients with suspected or known cardiac sarcoidosis. Using this information, we will identify integrative phenotypes – composed of biomarkers from cardiovascular magnetic resonance imaging, demographics, and clinical characteristics – associated with adverse cardiac outcomes. The proposed work will establish high- and low-risk phenotypes of cardiac sarcoidosis patients that predict benefit from immunosuppression and/or implantable cardioverter-defibrillators to prevent sudden arrhythmic cardiac death and other cardiac sarcoidosis-related adverse outcomes. These data will lay the groundwork for prospective studies testing the strategy of using the integrative phenotypes to select cardiac sarcoidosis patients for treatments. Selective and appropriate use of these treatments could improve long-term clinical outcomes in patients with cardiac sarcoidosis, in particular by preventing ventricular arrhythmia-related sudden cardiac death.

项目概要/摘要据估计，有 20 万美国人患有结节病。结节病是一种多系统肉芽肿性疾病病因不明。多达四分之一的结节病患者可能有心脏受累。心脏结节病是结节病相关死亡的第二大原因，占结节病相关死亡人数的四分之一死于结节病。大多数心脏结节病死亡是由于室性心律失常所致。心血管磁共振成像经常用于评估疑似或患有以下疾病的患者：已知的心脏结节病。在本提案中，我们的目标是研究心血管磁共振成像可能与疑似或已知心脏病患者的不良后果相关的生物标志物结节病。利用这些信息，我们将识别由生物标志物组成的综合表型心血管磁共振成像、人口统计学和临床特征——与不良的心脏后果。拟议的工作将建立心脏疾病的高风险和低风险表型预测免疫抑制和/或植入式心脏复律除颤器获益的结节病患者预防心律失常性猝死和其他心脏结节病相关的不良后果。这些数据将为前瞻性研究奠定基础，测试使用综合表型的策略选择心脏结节病患者进行治疗。选择性和适当地使用这些治疗方法可以改善心脏结节病患者的长期临床结果，特别是通过预防心室心律失常相关的心源性猝死。